TC |
Stat |
Stk |
Ins |
Fil |
+d |
+w |
+m |
+q |
+h |
+y |
avg |
|---|
Filing Date |
T Date |
Ticker |
Issuer | Inc | Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
3/13/23 18:30 | 3/3/23 | LHDX | Lucira Health, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Engelson Erik T. | CA | DO | P,Chief | M.d | 471 | 0.8200 | 0 | 575 | 261 | D | |||||||||||||||
3/13/23 18:30 | 3/3/23 | LHDX | Lucira Health, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Engelson Erik T. | CA | DO | P,Chief | S.d | -657 | 1.04 | 0 | -635 | -71 | 261 | D | ||||||||||||||
9/19/22 14:34 | 9/15/22 | LHDX | Lucira Health, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Engelson Erik T. | CA | DO | P,Chief | P | 36 | 1.82 | 0 | 20 | 7 | 321 | D | ||||||||||||||
6/17/22 18:45 | 6/16/22 | LHDX | Lucira Health, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Engelson Erik T. | CA | DO | P,Chief | P | 15 | 1.49 | 0 | 10 | 3 | 301 | D | ||||||||||||||
3/16/22 18:47 | 3/15/22 | LHDX | Lucira Health, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Engelson Erik T. | CA | DO | P,Chief | P | 90 | 3.00 | 0 | 30 | 11 | 291 | D |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |